Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Propeller Health

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

GSK buoyed by FDA panel backing for Advair successor

Committee votes in favour of Breo’s use in respiratory condition COPD

- PMLiVE

Sanofi supports Clexane with Spanish VTE apps

The free iPhone, iPad and Android apps are for healthcare professionals

- PMLiVE

Alkermes cuts jobs in Ireland as Novartis invests

130 jobs to go at manufacturing facility in Athlone as Novartis creates 100 roles in Dublin

- PMLiVE

Novartis says Indian Glivec verdict “discourages innovation”

Country's Supreme Court denies the cancer drug patent protection

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

FDA says final mobile app guidance just weeks away

And tells Congress only a fraction of mobile apps will need regulating

Vivus launches weight loss app to swell Qsymia sales

iPhone and Android Q and Me app backed up with patient support programme

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links